| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL3R; CD123; IL3RX; IL3RY; IL3RAY; hIL-3Ra |
| Entrez GeneID | 3563 |
| clone | 8E11C5 |
| WB Predicted band size | 43.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL3RA (AA: 200-305) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IL3RA抗体的3篇代表性文献的简要信息：
1. **标题**：Targeting IL-3RA in acute leukemia with a bispecific antibody
**作者**：Frankel AE et al.
**摘要**：研究开发了一种靶向IL3RA(CD123)和CD3的双特异性抗体，通过激活T细胞杀伤急性髓系白血病细胞，在小鼠模型中显示出显著抗肿瘤活性，为复发/难治性AML患者提供了新策略。
2. **标题**：CD123-antibody-drug conjugate induces apoptosis in systemic lupus erythematosus
**作者**：Karrar S et al.
**摘要**：发现IL3RA高表达于系统性红斑狼疮患者的浆细胞样树突状细胞。使用抗CD123抗体偶联药物可选择性清除这些异常细胞，在灵长类动物模型中有效缓解疾病活动度。
3. **标题**：Structural basis of IL-3 recognition by its antibody therapeutic
**作者**：Li J et al.
**摘要**：通过X射线晶体学解析了人源化抗IL3RA抗体(CSL362)与抗原的结合表位，揭示了其特异性阻断IL-3信号转导的结构机制，解释了该抗体在抑制白血病干细胞自我更新中的分子基础。
注：上述文献信息为领域内典型研究方向示例，实际文献检索建议通过PubMed或Web of Science使用关键词"IL3RA antibody"、"CD123 therapeutic"等获取最新研究。
The interleukin-3 receptor alpha (IL3RA, also known as CD123) is a subunit of the interleukin-3 receptor complex, which plays a critical role in regulating hematopoiesis and immune responses. As a type I cytokine receptor, IL3RA combines with the beta common chain (βc) to form a high-affinity receptor for IL-3. a cytokine involved in the survival, proliferation, and differentiation of hematopoietic progenitor cells, dendritic cells, and eosinophils. CD123 is prominently expressed on plasmacytoid dendritic cells (pDCs) and certain hematopoietic malignancies, making it a biomarker of interest in both immunology and oncology.
IL3RA-targeting antibodies have emerged as promising tools for research and therapeutic applications. In cancer, CD123 overexpression is observed in acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and some lymphoid malignancies, driving antibody-based therapies such as antibody-drug conjugates (e.g., tagraxofusp) and bispecific antibodies. In autoimmune diseases like lupus, targeting CD123+ pDCs aims to modulate aberrant interferon-alpha production. Research-grade IL3RA antibodies are widely used to study receptor expression, signaling pathways (e.g., JAK/STAT activation), and cellular interactions. Challenges include balancing therapeutic efficacy with potential off-target effects due to CD123's expression on healthy hematopoietic stem cells. Ongoing studies explore engineered antibodies to enhance specificity and reduce toxicity.
×
